GGG

GUARD THERAPEUTICS INTERNATIONAL AB

No trades
See on Supercharts
Market capitalization
‪299.84 M‬SEK
−11.2SEK
‪−113.32 M‬SEK
Beta (1Y)
−3.49

About GUARD THERAPEUTICS INTERNATIONAL AB

CEO
Tobias Larsson Agervald
Headquarters
Stockholm
Founded
2008
ISIN
SE0021181559
FIGI
BBG004D30VL8
Guard Therapeutics International AB is a pharmaceutical company, which engages in the research, development, and commercialization of medical treatment and diagnosis based on alpha-1-microglobulin. It focuses on the treatment of pre-eclampsia and acute kidney injury. The company was founded by Bo Åkerström, Tomas Jörgen Eriksson, Stefan Hansson, Gram Magnus on April 4, 2008 and is headquartered in Lund, Sweden.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
‪0.00‬
Summarizing what the indicators are suggesting.
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.

Frequently Asked Questions

The current price of GUARD is 30.0 SEK — it has increased by 0.67% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on OMXSTO exchange GUARD THERAPEUTICS INTERNATIONAL AB stocks are traded under the ticker GUARD.
GUARD THERAPEUTICS INTERNATIONAL AB is going to release the next earnings report on May 8, 2024. Keep track of upcoming events with our Earnings Calendar.
GUARD stock is 10.27% volatile and has beta coefficient of −3.49. Check out the list of the most volatile stocks — is GUARD THERAPEUTICS INTERNATIONAL AB there?
Yes, you can track GUARD THERAPEUTICS INTERNATIONAL AB financials in yearly and quarterly reports right on TradingView.
GUARD stock has risen by 31.58% compared to the previous week, the month change is a 75.44% rise, over the last year GUARD THERAPEUTICS INTERNATIONAL AB has showed a 365.12% increase.
GUARD net income for the last quarter is ‪−17.10 M‬ SEK, while the quarter before that showed ‪−23.34 M‬ SEK of net income which accounts for 26.76% change. Track more GUARD THERAPEUTICS INTERNATIONAL AB financial stats to get the full picture.
Today GUARD THERAPEUTICS INTERNATIONAL AB has the market capitalization of ‪299.84 M‬, it has increased by 8.57% over the last week.
No, GUARD doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, GUARD shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade GUARD THERAPEUTICS INTERNATIONAL AB stock right from TradingView charts — choose your broker and connect to your account.
GUARD reached its all-time high on May 12, 2015 with the price of 6126.2 SEK, and its all-time low was 5.2 SEK and was reached on May 30, 2023.
See other stocks reaching their highest and lowest prices.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So GUARD THERAPEUTICS INTERNATIONAL AB technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating GUARD THERAPEUTICS INTERNATIONAL AB stock shows the neutral signal. See more of GUARD THERAPEUTICS INTERNATIONAL AB technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.